Advances in Clinical and Experimental Medicine
2013, vol. 22, nr 6, November-December, p. 785–794
Publication type: original article
Proteomic Analysis of the Immunosuppressive Effects of Mesenchymal Stem Cells in a Rat Heart Transplantation Model
Analiza proteomiczna działania immunosupresyjnego mezenchymalnych komórek macierzystych na modelu zwierzęcym z wykorzystaniem serca szczurów
1 Department of Heart Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China
2 Department of Heart Surgery, Fifth Affiliated Hospital of Sun Yat-sen University, China
Background. Some reports suggest mesenchymal stem cells (MSCs) have immunosuppressive properties. However, conflicting evidence regarding the role of MSCs has emerged.
Objectives. To gain a better understanding of the immunosuppressive properties of mesenchymal stem cells (MSCs) in a rat heart transplantation model.
Material and Methods. MSCs were obtained from the femoral and tibial bone marrow of Sprague-Dawley rats and cultured. Heart-transplanted rats were allocated into a MSC-treated group and 2 control groups. On postoperative day 7, 1 rat was sacrificed and the pathological changes of heart tissues were assessed. Serum proteomic spectra were generated by surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry (SELDI-TOF-MS).
Results. Rat MSCs displayed the typical spindle-shaped morphology in culture and significantly prolonged the graft survival up to 33.25 ± 2.54 days compared with controls (19.75 ± 1.56 and 11.16 ± 1.34 days, respectively). Pathological analysis showed the inflammatory cell infiltration in the MSC-treated group was significantly reduced. SELDI analysis showed that 5 protein/peptide peaks with M/Z 1272.33, 1986.65, 2323.42, 5375.59 and 12968.11 were up-regulated in the MSC-treated group (P < 0.001).
Conclusion. Donor-derived MSCs clearly alleviate acute rejection following heart transplantation in rats and significantly prolong the isograft survival time
rat heart transplantation, immunosuppression, mesenchymal stem cells, SELDI ProteinChip, decision tree.
- Toma JG, McKenzie IA, Bagli D, Miller FD: Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 2005, 23, 727–737.
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13, 4279–4295.
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 43–47.
- Kim YH, Wee YM, Choi MY, Lim DG, Kim SC, Han DJ: Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 2011, 17, 697–708.
- Wan CD, Cheng R, Wang HB, Liu T: Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 2008, 7, 29–33.
- Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30, 42–48.
- Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, Liu JC, Zhang JZ, Wu TJ: Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006, 38: 3046–3051.
- Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, Hoogduijn MJ: Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009, 87, 896–906.
- Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi G, Noris M: Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181, 3933–3946.
- Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, Rossi L, Abbate R, Marseglia G, Nannetti G, Torricelli F, Miracco C, Bosi A, Fimiani M, Saccardi R: Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008, 300, 115–124.
- Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH: Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81, 1589–1595.
- Stagg J, Galipeau J: Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 2007, 45–66.
- Noël D, Djouad F, Bouffi C, Mrugala D, Jorgensen C: Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007, 48, 1283–1289.
- Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F: Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle: Transplantation 2007, 83, 71–76.
- Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110, 3499– –3506.
- Ryan JM, Barry FP, Murphy JM, Mahon BP: Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005, 2, 8.
- Ono K, Lindsey ES: Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969, 57, 225–229.
- Lin Q, Peng Q, Yao F, Pan XF, Xiong LW, Wang Y, Geng JF, Feng JX, Han BH, Bao GL, Yang Y, Wang X, Jin L, Guo W, Wang JC: A classification method based on principal components of SELDI spectra to diagnose of lung adenocarcinoma. PLoS One 2012; 7: e34457. DOI: 10.1371/journal.pone.0034457.
- Ge Z, Zhu YL, Zhong X, Yu JK, Zheng S: Discovering differential protein expression caused by CagA-induced ERK pathway activation in AGS cells using the SELDI-ProteinChip platform. World J Gastroenterol 2008, 14, 554–562.
- Carr CA, Stuckey DJ, Tatton L, Tyler DJ, Hale SJ, Sweeney D, Schneider JE, Martin-Rendon E, Radda GK, Harding SE, Watt SM, Clarke K: Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 2008, 295, 533–542.
- Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W, Mosca J, Sturgeon C, Siatskas M, Mahmud N, Ferrer K, Deans R, Moseley A, Hoffman R, Devine SM: Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001, 12, 1527–1541.
- Biancamaria L, Erzsèbet S, Lorenza P, Benedetta M, Giacomo TP, Serena U, Paola Quaranta1, SA, Sergio T, Marcella C, Riccardo S, Bruno N, Franco M: Mesenchymal stem cell-based immunomodulation in allogeneic heterotopic heart-lung transplantation. Transplantation Technologies & Research 2012. 2: p. DOI: 10.4172/2161- -0991.1000107.